<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17192" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Adenocarcinoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mullangi</surname>
            <given-names>Sanjana</given-names>
          </name>
          <aff>Hillcrest Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lekkala</surname>
            <given-names>Manidhar Reddy</given-names>
          </name>
          <aff>University of Rochester Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sanjana Mullangi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manidhar Reddy Lekkala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>18</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17192.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Adenocarcinomas are malignant tumors formed from glandular structures in epithelial tissue. They can arise from a variety of tissues. This activity reviews the etiology, epidemiology, pathology, evaluation, and management of adenocarcinomas of different organs and highlights the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the most common organs in which adenocarcinomas develop.</p></list-item><list-item><p>Review the evaluation of adenocarcinoma.</p></list-item><list-item><p>Outline the management options available for adenocarcinomas.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17192&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17192">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17192.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Adenocarcinoma is a malignant neoplasm arising from epithelial cells of the glands or glandular like structures. Adenocarcinoma can arise in multiple sites of the body. Some of the common sites that develop adenocarcinoma are the breast, lung, prostate, and gastrointestinal tract, like the colon, rectum, pancreas, stomach, and esophagus. Adenocarcinomas also make up 70 percent of cancer of unknown origin.<xref ref-type="bibr" rid="article-17192.r1">[1]</xref></p>
      </sec>
      <sec id="article-17192.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>A number of environmental as well as lifestyle risk factors are associated with the development of cancers. Different sites have different carcinogens and risk factors. Tobacco smoking, by far, seems to play a major role in most of them.</p>
        <p>
<bold>Adenocarcinoma of Lung</bold>
</p>
        <p>Smoking is a significant risk factor associated with lung cancer, with more than 90 percent of cases related to it.<xref ref-type="bibr" rid="article-17192.r2">[2]</xref>&#x000a0;Other risk factors include exposure to radiation, environmental toxins like arsenic, chromium, nickel, and polycarbonate, pulmonary fibrosis, scarring of the lung, and genetic causes.<xref ref-type="bibr" rid="article-17192.r2">[2]</xref><xref ref-type="bibr" rid="article-17192.r3">[3]</xref></p>
        <p>
<bold>
<bold>Adenocarcinoma of Breast</bold>
</bold>
</p>
        <p>Breast cancer is the most common cancer diagnosis in the world and the United States. Female gender, excess estrogen exposure states like nulliparity, late pregnancy, early menarche, late menopause, external estrogen exposure, and alcohol are some of the risk factors for breast cancer.<xref ref-type="bibr" rid="article-17192.r4">[4]</xref>&#x000a0;Genetic factors with mutations in the BRCA1/2, p53, PTEN, PALB2, etc, and family history increase the risk of breast adenocarcinoma.<xref ref-type="bibr" rid="article-17192.r5">[5]</xref></p>
        <p>
<bold>Adenocarcinoma of Prostate</bold>
</p>
        <p>The most important risk factor for prostate adenocarcinoma is age. Patients clinically diagnosed with prostate cancer before age 40 are very rare.<xref ref-type="bibr" rid="article-17192.r6">[6]</xref>&#x000a0;Other risk factors include cigarette smoking, family history of prostate cancer as well as germline mutations like BRCA2/1 and ATM.<xref ref-type="bibr" rid="article-17192.r7">[7]</xref></p>
        <p>
<bold>Adenocarcinoma of the Colon/Rectum</bold>
</p>
        <p>Environmental and genetic factors increase the risk of colorectal cancer. Many hereditary colorectal cancer syndromes like the familial adenomatous polyposis, Lynch syndrome, and other non-Lynch syndromes like the biallelic MUTYH, BRCA1/2, PALB2, CDKN2A, TP53, FAP increases the risk of colorectal cancer.<xref ref-type="bibr" rid="article-17192.r8">[8]</xref><xref ref-type="bibr" rid="article-17192.r9">[9]</xref><xref ref-type="bibr" rid="article-17192.r10">[10]</xref> Other risk factors include personal or family history, inflammatory bowel disease, red and processed meat, tobacco use, and alcohol also increase the risk.</p>
        <p>
<bold>Adenocarcinoma of the Pancreas</bold>
</p>
        <p>Environmental risk factors contributing to pancreatic adenocarcinoma include smoking, high fasting plasma glucose, high body mass index, western diet, and alcohol consumption, prolonged use of aspirin.<xref ref-type="bibr" rid="article-17192.r11">[11]</xref> Hereditary risk factors also contribute to the risk, with up to 10 percent of individuals with pancreatic cancer having a family history.<xref ref-type="bibr" rid="article-17192.r12">[12]</xref><xref ref-type="bibr" rid="article-17192.r13">[13]</xref>&#x000a0;ABO blood type has been associated with several gastrointestinal cancers, including pancreatic cancer as well as cystic fibrosis, with 2 to 5-fold higher risk in patients who have undergone a lung transplant.<xref ref-type="bibr" rid="article-17192.r14">[14]</xref><xref ref-type="bibr" rid="article-17192.r15">[15]</xref><xref ref-type="bibr" rid="article-17192.r16">[16]</xref><xref ref-type="bibr" rid="article-17192.r17">[17]</xref><xref ref-type="bibr" rid="article-17192.r18">[18]</xref> The amount of cigarette smoking significantly increases</p>
        <p>the risk of adenocarcinoma of the pancreas,&#x000a0;<xref ref-type="bibr" rid="article-17192.r19">[19]</xref><xref ref-type="bibr" rid="article-17192.r20">[20]</xref><xref ref-type="bibr" rid="article-17192.r21">[21]</xref><xref ref-type="bibr" rid="article-17192.r22">[22]</xref><xref ref-type="bibr" rid="article-17192.r23">[23]</xref>&#x000a0;a population-attributable fraction of deaths due to pancreatic cancer associated with smoking is 11% to 32%.<xref ref-type="bibr" rid="article-17192.r24">[24]</xref></p>
        <p>Other important risk factors include H. pylori in gastric adenocarcinoma<xref ref-type="bibr" rid="article-17192.r25">[25]</xref>, gastroesophageal reflux disease (GERD), and alcohol in esophageal adenocarcinoma.<xref ref-type="bibr" rid="article-17192.r26">[26]</xref></p>
      </sec>
      <sec id="article-17192.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>
<bold>Adenocarcinoma of Lung</bold>
</p>
        <p>Lung cancer is the most common cause of cancer, the leading cause of death in men in the world, and the second leading cause in women.<xref ref-type="bibr" rid="article-17192.r4">[4]</xref>&#x000a0;Forty percent of lung cancers are secondary to adenocarcinoma. There are significant differences in the incidence of lung cancer from one country to another, mostly attributed to the prevalence of smoking. Tobacco control efforts are going to reduce the incidence of lung cancer in the future.<xref ref-type="bibr" rid="article-17192.r27">[27]</xref></p>
        <p>
<bold>Adenocarcinoma of Breast</bold>
</p>
        <p>Breast Cancer is the second most common cause of cancer worldwide and the most common cancer in women.<xref ref-type="bibr" rid="article-17192.r28">[28]</xref>&#x000a0;The incidence of breast cancer is higher in the white countries compared to the Asian and African nations.<xref ref-type="bibr" rid="article-17192.r29">[29]</xref>&#x000a0;Breast cancer mortality has been in decline, largely attributed to screening measures and adjuvant therapy.<xref ref-type="bibr" rid="article-17192.r30">[30]</xref><xref ref-type="bibr" rid="article-17192.r31">[31]</xref></p>
        <p>
<bold>Adenocarcinoma of Prostate</bold>
</p>
        <p>Adenocarcinoma of the prostate is the second most common cancer in men worldwide. It is the third leading cause of death in the United States.<xref ref-type="bibr" rid="article-17192.r32">[32]</xref><xref ref-type="bibr" rid="article-17192.r4">[4]</xref>&#x000a0;Prostate cancer mortality is on a decline, especially in the United States, which is attributed to increased screening as well as adjuvant therapies.<xref ref-type="bibr" rid="article-17192.r32">[32]</xref><xref ref-type="bibr" rid="article-17192.r4">[4]</xref></p>
        <p>
<bold>Adenocarcinoma of Colon/Rectum</bold>
</p>
        <p>Colorectal cancers are the third most common cancer in males and second in females.<xref ref-type="bibr" rid="article-17192.r4">[4]</xref>&#x000a0;In the United States, the annual incidence, as well as mortality, is slowly decreasing.<xref ref-type="bibr" rid="article-17192.r33">[33]</xref>&#x000a0;The incidence of colorectal cancers varies globally, with the highest incidence rates in Australia, New Zealand, Europe, and North America, whereas the lowest is seen in Africa and Southcentral Asia. People with low socioeconomic status also tend to have an increase in the incidence of colorectal cancer.&#x000a0;</p>
        <p>
<bold>Adenocarcinoma of Pancreas</bold>
</p>
        <p>Pancreatic cancer is the fourth leading cause of oncologic related death in both men and women. More than 85% of the cases comprise of adenocarcinoma. Incidence increases with age and is rare before the age of 45. It peaks at age 65 to 69 in men and 75&#x000a0;to 79 in women.<xref ref-type="bibr" rid="article-17192.r34">[34]</xref>&#x000a0;It has been mostly reported in the Western world, with the highest incidence in high-income groups living in North America and Western and Central Europe. The lowest incidence was reported in South Asia and Central and Eastern Sub-Saharan Africa.<xref ref-type="bibr" rid="article-17192.r34">[34]</xref>&#x000a0;In the United States, incidence seems to be higher in males and predominantly seen in African Americans.</p>
      </sec>
      <sec id="article-17192.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Adenocarcinomas are easily diagnosed and distinguished from other cancer histologies by a light microscopy examination. The diagnosis is usually based on the identification of glandular structures under light microscopy. As these features are shared by all types of adenocarcinomas, it is impossible to diagnose the primary site of origin of these tumors, especially in a metastatic setting. Also, with poorly differentiated adenocarcinomas, where minimal glandular formation is seen on light microscopy or no glandular formation but stain for mucin, immunohistochemistry (IHC) is an important tool to help further diagnose the type of adenocarcinoma.<xref ref-type="bibr" rid="article-17192.r35">[35]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Positive staining for CK-7 along with TTF-1 (+/- napsin), which is a pneumocyte marker expressor, is highly suggestive of adenocarcinoma of the lung. Adenocarcinoma of the lung also tends to have mutations in the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ROS oncogene 1(ROS-1), which are important to diagnose, as targeted therapies are available for treatment. PD-L1 IHC assays are also performed in advanced lung cancers to help with treatment selection with immunotherapy. The College of American Pathologists recommends obtaining the above testing on all patients with advanced adenocarcinoma of the lung.<xref ref-type="bibr" rid="article-17192.r36">[36]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Positive staining for CK-7, GATA -3 ( GATA-binding protein 3), and gross cystic fluid protein 15 is suggestive of breast adenocarcinoma.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Positive staining for prostate-specific antigen (PSA) is specific for adenocarcinoma of the prostate. P63, a nuclear basal protein, helps to differentiate from normal prostatic tissue and adenocarcinoma of the prostate.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Positive CDX-2 or cytokeratin-20 (CK-20) positive with CK-7 negative, is suggestive of colorectal adenocarcinoma.</p>
          </list-item>
          <list-item>
            <p>Positive staining for CK-7, PAX 8, and WT-1 is suggestive of ovarian adenocarcinoma.</p>
          </list-item>
          <list-item>
            <p>Positive staining for thyroglobulin and thyroid transcription factor-1 is suggestive of adenocarcinoma of the thyroid.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17192.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The clinical presentation of patients with adenocarcinoma will vary according to the primary site of involvement by the tumor and the extent of other organs involved. Obtaining a family history from the patient plays a significant role, as some of the cancers are inherited. Patients can be asymptomatic or have nonspecific symptoms like unintended weight loss and other symptoms depending on the organ's involvement with metastasis. The most commonly involved sites include the bones, lungs, liver, and lymph nodes, which represent nearly 60 percent of the cases. The most common type of adenocarcinomas comprises breast, lung, prostate, colorectal, and pancreatic.&#x000a0;</p>
        <p>Adenocarcinoma of the breast may present with common symptoms like sudden onset of pain or after trauma, nipple discharge/inversion, new persistent skin changes, and palpable breast mass, which could be found as an incidental finding or at a routine wellness exam.<xref ref-type="bibr" rid="article-17192.r37">[37]</xref><xref ref-type="bibr" rid="article-17192.r38">[38]</xref></p>
        <p>Adenocarcinoma of the lung can present with a chronic dry cough, dyspnea, hemoptysis, weight loss, or as an incidental finding on routine imaging. Lung adenocarcinoma is associated with extrapulmonary features like hypertrophic osteoarthropathy, which manifests as clubbing, periostitis of long bones, and arthritis.</p>
        <p>Adenocarcinoma of prostate patients may present with difficulty urination, weak stream, incomplete emptying of the bladder, occasionally hematuria, and chronic back pain. On exam, enlarged prostate, abnormal DRE exam, although this has low sensitivity and specificity.<xref ref-type="bibr" rid="article-17192.r39">[39]</xref></p>
        <p>Adenocarcinoma of the colon and rectum can present as unintentional weight loss, fatigue, generalized weakness, hematochezia, abdominal pain, and bowel obstruction.&#x000a0;Adenocarcinoma of the pancreas can present as chronic epigastric pain, nausea, vomiting, jaundice, weight loss, anorexia, asthenia, steatorrhea, hepatosplenomegaly, and thrombophlebitis.<xref ref-type="bibr" rid="article-17192.r40">[40]</xref></p>
      </sec>
      <sec id="article-17192.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Initial evaluation for a diagnosis of adenocarcinoma starts with a thorough, complete history and a physical exam. Lab work should include complete blood counts, a comprehensive metabolic panel, and urinalysis. Imaging studies are usually obtained depending on the suspicion of the primary site of adenocarcinoma as well as metastatic disease.</p>
        <p>Computed tomography (CT) scan of the chest, abdomen, and pelvis with contrast and, in some instances, magnetic resonance imaging (MRI) are usually helpful in evaluation for a primary site of cancer. Gender-specific screening, for example, prostate exam as well as levels of PSA levels in a patient suspicious for prostatic adenocarcinoma and a complete breast and pelvis exam, including a pap smear and mammogram in females suspicious for breast cancer. Positron emission tomography (PET) scan can be helpful in identifying a primary site in 40 percent of the cases in a retrospective study and is also used for appropriate staging.<xref ref-type="bibr" rid="article-17192.r41">[41]</xref><xref ref-type="bibr" rid="article-17192.r42">[42]</xref>&#x000a0;However, the use of PET scans was not found to be superior to CT scans in a prospective study.<xref ref-type="bibr" rid="article-17192.r43">[43]</xref>&#x000a0;</p>
        <p>Patients with concern for a gastrointestinal tumor should be evaluated with a colonoscopy, upper endoscopy with endoscopic ultrasound (EUS), and endoscopic retrograde cholangiopancreatography(ERCP), depending on the suspicion for the origin of the primary tumor. Colonoscopy is also recommended for a colorectal origin tumor when an intra-abdominal metastasis has CK20/ CK7 negative on the IHC staining pattern. Once a biopsy is obtained, further microscopic examination, as well as IHC staining, will help accurately diagnose the type of adenocarcinoma.&#x000a0;</p>
        <p>Biomarkers like the CEA, CA 19-9, CA 125, etc, are not sensitive for diagnostic purposes but can be used to monitor response to therapy as well as an indicator of the activity of disease at the time of diagnosis.<xref ref-type="bibr" rid="article-17192.r44">[44]</xref><xref ref-type="bibr" rid="article-17192.r45">[45]</xref><xref ref-type="bibr" rid="article-17192.r46">[46]</xref><xref ref-type="bibr" rid="article-17192.r47">[47]</xref><xref ref-type="bibr" rid="article-17192.r48">[48]</xref>&#x000a0;CA 15-3 and CA 27.29 are commonly used in metastatic breast cancer to monitor disease status for patients undergoing treatment.<xref ref-type="bibr" rid="article-17192.r49">[49]</xref></p>
      </sec>
      <sec id="article-17192.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Adenocarcinomas are diverse and can involve any part of the body. The management and treatment of adenocarcinoma differ depending on the primary site of disease as well as the stage of cancer. Prior to the initiation of any treatment, it is very important first to characterize the site and type of adenocarcinoma.&#x000a0;Interprofessional&#x000a0;care is of utmost importance, with the involvement of pathology, radiology, surgical oncology, radiation oncology, and medical oncology, along with other allied health professionals. In the earlier stages of cancer, where surgical resection is feasible, surgery offers the best opportunity for long-term survival. Depending on the location, type, stage, as well as performance status of the patient, different types of treatments are proposed.</p>
        <p>Curative intent treatments usually include surgery, neoadjuvant or adjuvant systemic chemotherapy, radiation therapy, or a combination of concurrent radiation and chemotherapy, hormonal therapy in breast and prostate cancer. Management also involves close follow up of these patients with repeat blood work, surveillance scans, and long term symptom and survivorship care. Palliative treatment is proposed in the incurable setting and usually involves systemic chemotherapy, immunotherapy, and targeted therapies to prolong the survival of the patient. There is a role for palliative radiation and surgery for symptom control.</p>
      </sec>
      <sec id="article-17192.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis can be broad depending on the site of adenocarcinoma.</p>
        <list list-type="bullet">
          <list-item>
            <p>Adenocarcinoma of the lung: Benign lung tumors, infection, small cell lung cancer, metastasis from another primary cancer, tuberculosis.</p>
          </list-item>
          <list-item>
            <p>Adenocarcinoma of the breast: Fibroadenoma, breast abscess, traumatic fat necrosis, breast lymphoma, metastasis from another primary cancer.</p>
          </list-item>
          <list-item>
            <p>Adenocarcinoma of the prostate: Prostatitis, prostatic abscess, benign prostatic hyperplasia, sarcoma of the prostate, metastasis from another primary cancer.</p>
          </list-item>
          <list-item>
            <p>Adenocarcinoma of colon and rectum: Crohn disease, ulcerative colitis, diverticulosis, intestinal lymphoma, metastatic cancer from another primary site, carcinoid.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17192.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of adenocarcinoma depends on the type of adenocarcinoma as well as the stage of cancer at diagnosis. The tumor, node, and metastasis (TNM) staging has the greatest impact on prognosis. Other independent factors that determine prognosis are the performance status of the patient, site of metastasis, tumor burden, eligibility, and tolerance of treatment.<xref ref-type="bibr" rid="article-17192.r50">[50]</xref><xref ref-type="bibr" rid="article-17192.r51">[51]</xref><xref ref-type="bibr" rid="article-17192.r52">[52]</xref><xref ref-type="bibr" rid="article-17192.r53">[53]</xref>&#x000a0;</p>
        <p>Below are the SEER data on survival on different sites of adenocarcinoma, where a significant survival difference is noted between different adenocarcinomas depending on the site of origin.</p>
        <list list-type="bullet">
          <list-item>
            <p>Adenocarcinoma of the lung: the 5-year survival rate: Localized: 59%Regional: 31.7%Distant: 5.8%</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Adenocarcinoma of the breast: the 5-year survival rateLocalized: 98.9%Regional: 85.7%Distant: 28.1%</p>
          </list-item>
          <list-item>
            <p>Adenocarcinoma of the prostate: the 5-year survival rateLocalized: 100%Regional: 100%Distant: 30.2%</p>
          </list-item>
          <list-item>
            <p>Adenocarcinoma of colorectal origin: the 5-year survival Localized: 90.2%Regional: 71.8%Distant: 14.3%</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17192.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of adenocarcinoma are primarily related to the cancer site, the extent of the tumor, metastatic area. Other complications associated with adenocarcinoma are related to the management options.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Tumor complications:&#x000a0;</bold>Pain, generalized weakness, failure to thrive, weight loss and death&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Surgery complications:&#x000a0;</bold>Postoperative infections, perforation, bleeding risk, anesthetic complications&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Chemotherapy complications: </bold>Pancytopenia, life-threatening complications secondary to immunocompromised state, kidney and liver dysfunction, neuropathy, anaphylaxis</p>
          </list-item>
          <list-item>
            <p><bold>Immunotherapy complications: </bold>Colitis, skin rash, thyroiditis, pneumonitis, psoriasis, pneumonitis, pericarditis&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Radiation complications: </bold>Inflammation of surrounding organs, skin rash, neuropathies, mucositis, the progression of coronary artery disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17192.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education should be considered an important aspect when it comes to better management of any disease. In the context of adenocarcinoma, patient education regarding the importance of recognition of any concerning symptoms is of utmost importance. Clinicians need to maintain a good doctor-patient relationship, allowing them to covey their concerns freely.</p>
        <p>The patient should receive education regarding the following:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Type of adenocarcinoma</p>
          </list-item>
          <list-item>
            <p>Importance of staging in adenocarcinoma</p>
          </list-item>
          <list-item>
            <p>Availability of tests and procedures for the diagnosis of adenocarcinoma</p>
          </list-item>
          <list-item>
            <p>Risks and benefits associated with available treatments and side effects associated with specific treatments</p>
          </list-item>
          <list-item>
            <p>Importance of interdisciplinary care in the management of adenocarcinoma and surveillance</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17192.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Adenocarcinoma is a common diagnosis, and the management of these invasive cancers is complex depending on the primary site, stage of cancer, and performance status of the patient. Various&#x000a0;healthcare providers are involved in the management of adenocarcinoma, including pathologists, surgical oncologists, radiation oncologists, medical oncologists, primary care physicians, radiologists, nurses, and pharmacists.&#x000a0;</p>
        <p>Effective management of the disease requires excellent interpersonal communication and collaboration between team members to provide improved patient-centered care. An interdisciplinary tumor board discussion is recommended in the management of these patients, which helps with effective communication, timely treatment planning, and good outcomes. Involving the patients and their families in treatment decisions improves outcomes in these patient populations.&#x000a0;Most importantly, screening and management guidelines exist as a result of various conferences and exhaustive research (clinical trials, meta-analysis, systematic reviews) where healthcare providers come and work together towards common goals and share their ideas.</p>
        <p>Revision of guidelines is critical to incorporate better, practical, and more feasible methods. In situations where enough data isn't available, expert opinion from a specialist may be taken to help better guide management. All this is possible with effective communication and coordination of care amongst different healthcare providers.<xref ref-type="bibr" rid="article-17192.r54">[54]</xref></p>
      </sec>
      <sec id="article-17192.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17192&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17192">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/adenocarcinoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17192">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17192/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17192">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17192.s15">
        <title>References</title>
        <ref id="article-17192.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pentheroudakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Golfinopoulos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pavlidis</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Switching benchmarks in cancer of unknown primary: from autopsy to microarray.</article-title>
            <source>Eur J Cancer</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>14</issue>
            <fpage>2026</fpage>
            <page-range>2026-36</page-range>
            <pub-id pub-id-type="pmid">17698346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alberg</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Samet</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of lung cancer.</article-title>
            <source>Chest</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>123</volume>
            <issue>1 Suppl</issue>
            <fpage>21S</fpage>
            <page-range>21S-49S</page-range>
            <pub-id pub-id-type="pmid">12527563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hubbard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Venn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Britton</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>161</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-8</page-range>
            <pub-id pub-id-type="pmid">10619790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer statistics, 2020.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>70</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-30</page-range>
            <pub-id pub-id-type="pmid">31912902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoiness</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Huether</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sridhar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>McFarland</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dolinsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tippin Davis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mexal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dunlop</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.</article-title>
            <source>JAMA Oncol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-57</page-range>
            <pub-id pub-id-type="pmid">30128536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delongchamps</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>The role of prevalence in the diagnosis of prostate cancer.</article-title>
            <source>Cancer Control</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>158</fpage>
            <page-range>158-68</page-range>
            <pub-id pub-id-type="pmid">16885911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicolosi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ledet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Michalski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Freschi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>O'Leary</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Esplin</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Nussbaum</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Sartor</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.</article-title>
            <source>JAMA Oncol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>523</fpage>
            <page-range>523-528</page-range>
            <pub-id pub-id-type="pmid">30730552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burt</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>DiSario</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cannon-Albright</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Genetics of colon cancer: impact of inheritance on colon cancer risk.</article-title>
            <source>Annu Rev Med</source>
            <year>1995</year>
            <volume>46</volume>
            <fpage>371</fpage>
            <page-range>371-9</page-range>
            <pub-id pub-id-type="pmid">7598472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lynch</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Smyrk</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lanspa</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Cavalieri</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review.</article-title>
            <source>Gastroenterology</source>
            <year>1993</year>
            <month>May</month>
            <volume>104</volume>
            <issue>5</issue>
            <fpage>1535</fpage>
            <page-range>1535-49</page-range>
            <pub-id pub-id-type="pmid">8482467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yurgelun</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Kulke</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Uno</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hornick</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ukaegbu</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Brais</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>McNamara</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Schrag</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Meyerhardt</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kidd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hartman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Wenstrup</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Syngal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.</article-title>
            <source>J Clin Oncol</source>
            <year>2017</year>
            <month>Apr</month>
            <day>01</day>
            <volume>35</volume>
            <issue>10</issue>
            <fpage>1086</fpage>
            <page-range>1086-1095</page-range>
            <pub-id pub-id-type="pmid">28135145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schernhammer</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Giovannucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Colditz</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>A prospective study of aspirin use and the risk of pancreatic cancer in women.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2004</year>
            <month>Jan</month>
            <day>07</day>
            <volume>96</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-8</page-range>
            <pub-id pub-id-type="pmid">14709735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Hruban</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Brune</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Goggins</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Familial pancreatic cancer.</article-title>
            <source>Cancer J</source>
            <year>2001</year>
            <season>Jul-Aug</season>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>266</fpage>
            <page-range>266-73</page-range>
            <pub-id pub-id-type="pmid">11561603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olson</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kurtz</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of pancreatic cancer and the role of family history.</article-title>
            <source>J Surg Oncol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>107</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">22589078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolpin</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Hartge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chanock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kraft</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Giovannucci</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>ABO blood group and the risk of pancreatic cancer.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2009</year>
            <month>Mar</month>
            <day>18</day>
            <volume>101</volume>
            <issue>6</issue>
            <fpage>424</fpage>
            <page-range>424-31</page-range>
            <pub-id pub-id-type="pmid">19276450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Annese</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Minervini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gabbrielli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gambassi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Manna</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>ABO blood groups and cancer of the pancreas.</article-title>
            <source>Int J Pancreatol</source>
            <year>1990</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>81</fpage>
            <page-range>81-8</page-range>
            <pub-id pub-id-type="pmid">2230362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Risch</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kidd</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2010</year>
            <month>Apr</month>
            <day>07</day>
            <volume>102</volume>
            <issue>7</issue>
            <fpage>502</fpage>
            <page-range>502-5</page-range>
            <pub-id pub-id-type="pmid">20181960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolpin</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Kraft</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Helzlsouer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bueno-de-Mesquita</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Steplowski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stolzenberg-Solomon</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Arslan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Lacroix</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Albanes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Amundadottir</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Boutron-Ruault</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Buring</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Canzian</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chanock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Clipp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gaziano</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Giovannucci</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Hallmans</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hankinson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Hoover</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kooperberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mendelsohn</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Overvad</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Rajkovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanch&#x000e9;z</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>XO</given-names>
              </name>
              <name>
                <surname>Slimani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tobias</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Trichopoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vineis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Virtamo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wactawski-Wende</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zeleniuch-Jacquotte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hartge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium.</article-title>
            <source>Cancer Res</source>
            <year>2010</year>
            <month>Feb</month>
            <day>01</day>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>1015</fpage>
            <page-range>1015-23</page-range>
            <pub-id pub-id-type="pmid">20103627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Komaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Komaki</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Micic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zullow</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sakuraba</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis.</article-title>
            <source>Lancet Oncol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>758</fpage>
            <page-range>758-767</page-range>
            <pub-id pub-id-type="pmid">29706374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rebours</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>L&#x000e9;vy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>An overview of hereditary pancreatitis.</article-title>
            <source>Dig Liver Dis</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-15</page-range>
            <pub-id pub-id-type="pmid">21907651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lowenfels</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Maisonneuve</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Whitcomb</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for cancer in hereditary pancreatitis. International Hereditary Pancreatitis Study Group.</article-title>
            <source>Med Clin North Am</source>
            <year>2000</year>
            <month>May</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>565</fpage>
            <page-range>565-73</page-range>
            <pub-id pub-id-type="pmid">10872414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lynch</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Vrieling</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lubin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kraft</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mendelsohn</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Hartge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Canzian</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Steplowski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Arslan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Helzlsouer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>LaCroix</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Albanes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amundadottir</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bingham</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Boffetta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Boutron-Ruault</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Chanock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Clipp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoover</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Kooperberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Palli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Riboli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>XO</given-names>
              </name>
              <name>
                <surname>Rodriguez Suarez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tj&#x000f8;nneland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tobias</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Trichopoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Virtamo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zeleniuch-Jacquette</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bueno-de-Mesquita</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Stolzenberg-Solomon</surname>
                <given-names>RZ</given-names>
              </name>
            </person-group>
            <article-title>Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium.</article-title>
            <source>Am J Epidemiol</source>
            <year>2009</year>
            <month>Aug</month>
            <day>15</day>
            <volume>170</volume>
            <issue>4</issue>
            <fpage>403</fpage>
            <page-range>403-13</page-range>
            <pub-id pub-id-type="pmid">19561064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>N&#x000f6;thlings</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Wilkens</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Hankin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Kolonel</surname>
                <given-names>LN</given-names>
              </name>
            </person-group>
            <article-title>Meat and fat intake as risk factors for pancreatic cancer: the multiethnic cohort study.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2005</year>
            <month>Oct</month>
            <day>05</day>
            <volume>97</volume>
            <issue>19</issue>
            <fpage>1458</fpage>
            <page-range>1458-65</page-range>
            <pub-id pub-id-type="pmid">16204695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bosetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lucenteforte</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bracci</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Negri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Risch</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Gallinger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Bueno-de-Mesquita</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Talamini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Polesel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ghadirian</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baghurst</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Zatonski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Fontham</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bamlet</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Holly</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bertuccio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kurtz</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Cotterchio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maisonneuve</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Duell</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Boffetta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>La Vecchia</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4).</article-title>
            <source>Ann Oncol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>7</issue>
            <fpage>1880</fpage>
            <page-range>1880-8</page-range>
            <pub-id pub-id-type="pmid">22104574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maisonneuve</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lowenfels</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for pancreatic cancer: a summary review of meta-analytical studies.</article-title>
            <source>Int J Epidemiol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>186</fpage>
            <page-range>186-98</page-range>
            <pub-id pub-id-type="pmid">25502106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wroblewski</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Peek</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Helicobacter pylori, Cancer, and the Gastric Microbiota.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2016</year>
            <volume>908</volume>
            <fpage>393</fpage>
            <page-range>393-408</page-range>
            <pub-id pub-id-type="pmid">27573782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xie</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lagergren</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for oesophageal cancer.</article-title>
            <source>Best Pract Res Clin Gastroenterol</source>
            <year>2018</year>
            <season>Oct-Dec</season>
            <volume>36-37</volume>
            <fpage>3</fpage>
            <page-range>3-8</page-range>
            <pub-id pub-id-type="pmid">30551854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holford</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Feuer</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Meza</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach.</article-title>
            <source>Ann Intern Med</source>
            <year>2018</year>
            <month>Nov</month>
            <day>20</day>
            <volume>169</volume>
            <issue>10</issue>
            <fpage>684</fpage>
            <page-range>684-693</page-range>
            <pub-id pub-id-type="pmid">30304504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>BO</given-names>
              </name>
              <name>
                <surname>Yip</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Shyyan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sener</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Eniu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Azavedo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Harford</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007.</article-title>
            <source>Cancer</source>
            <year>2008</year>
            <month>Oct</month>
            <day>15</day>
            <volume>113</volume>
            <issue>8 Suppl</issue>
            <fpage>2221</fpage>
            <page-range>2221-43</page-range>
            <pub-id pub-id-type="pmid">18816619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torre</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Ferlay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lortet-Tieulent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Global cancer statistics, 2012.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>65</volume>
            <issue>2</issue>
            <fpage>87</fpage>
            <page-range>87-108</page-range>
            <pub-id pub-id-type="pmid">25651787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Gelder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heijnsdijk</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Fracheboud</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Draisma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Koning</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy.</article-title>
            <source>Int J Cancer</source>
            <year>2015</year>
            <month>Jul</month>
            <day>01</day>
            <volume>137</volume>
            <issue>1</issue>
            <fpage>165</fpage>
            <page-range>165-72</page-range>
            <pub-id pub-id-type="pmid">25430053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munoz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Near</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>van Ravesteyn</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Schechter</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Alagoz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Burnside</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chisholm</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Koning</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Ali Ergun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heijnsdijk</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stout</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Sprague</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Trentham-Dietz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mandelblatt</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Plevritis</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>106</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">25255803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bray</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ferlay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soerjomataram</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Torre</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>6</issue>
            <fpage>394</fpage>
            <page-range>394-424</page-range>
            <pub-id pub-id-type="pmid">30207593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Henley</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Feuer</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Firth</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Benard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cronin</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Annual Report to the Nation on the Status of Cancer, Featuring Cancer in Men and Women Age 20-49 Years.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2019</year>
            <month>Dec</month>
            <day>01</day>
            <volume>111</volume>
            <issue>12</issue>
            <fpage>1279</fpage>
            <page-range>1279-1297</page-range>
            <pub-id pub-id-type="pmid">31145458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <collab>GBD 2017 Pancreatic Cancer Collaborators</collab>
            <article-title>The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.</article-title>
            <source>Lancet Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>12</issue>
            <fpage>934</fpage>
            <page-range>934-947</page-range>
            <pub-id pub-id-type="pmid">31648972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greco</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Lennington</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Spigel</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Hainsworth</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.</article-title>
            <source>Mol Diagn Ther</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-7</page-range>
            <pub-id pub-id-type="pmid">25758902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindeman</surname>
                <given-names>NI</given-names>
              </name>
              <name>
                <surname>Cagle</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Beasley</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Chitale</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Dacic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giaccone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Kwiatkowski</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Saldivar</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Squire</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thunnissen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ladanyi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.</article-title>
            <source>J Thorac Oncol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>823</fpage>
            <page-range>823-59</page-range>
            <pub-id pub-id-type="pmid">23552377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morrow</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The evaluation of common breast problems.</article-title>
            <source>Am Fam Physician</source>
            <year>2000</year>
            <month>Apr</month>
            <day>15</day>
            <volume>61</volume>
            <issue>8</issue>
            <fpage>2371</fpage>
            <page-range>2371-8, 2385</page-range>
            <pub-id pub-id-type="pmid">10794579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santen</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Mansel</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Benign breast disorders.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Jul</month>
            <day>21</day>
            <volume>353</volume>
            <issue>3</issue>
            <fpage>275</fpage>
            <page-range>275-85</page-range>
            <pub-id pub-id-type="pmid">16034013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naji</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Randhawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sohani</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Dennis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lautenbach</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kavanagh</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bawor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Banfield</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Profetto</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis.</article-title>
            <source>Ann Fam Med</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>149</fpage>
            <page-range>149-154</page-range>
            <pub-id pub-id-type="pmid">29531107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fabregat</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Malats</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Guarner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carrato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Miguel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jariod</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Costafreda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coll</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alguacil</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Corominas</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sol&#x000e0;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Real</surname>
                <given-names>FX</given-names>
              </name>
            </person-group>
            <article-title>Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage.</article-title>
            <source>Clin Transl Oncol</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>189</fpage>
            <page-range>189-97</page-range>
            <pub-id pub-id-type="pmid">15960930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e8;ve</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Billotey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Broussolle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dumontet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site.</article-title>
            <source>Cancer</source>
            <year>2007</year>
            <month>Jan</month>
            <day>15</day>
            <volume>109</volume>
            <issue>2</issue>
            <fpage>292</fpage>
            <page-range>292-9</page-range>
            <pub-id pub-id-type="pmid">17167760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moller</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Loft</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berthelsen</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Damgaard Pedersen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Graff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Perell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Daugaard</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site: a literature review.</article-title>
            <source>Oncologist</source>
            <year>2011</year>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>445</fpage>
            <page-range>445-51</page-range>
            <pub-id pub-id-type="pmid">21427201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000f8;ller</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Loft</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berthelsen</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Graff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Skovgaard</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Perell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Daugaard</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site.</article-title>
            <source>Oncologist</source>
            <year>2012</year>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>1146</fpage>
            <page-range>1146-54</page-range>
            <pub-id pub-id-type="pmid">22711751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maisey</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Massey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oates</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.</article-title>
            <source>Br J Cancer</source>
            <year>2005</year>
            <month>Oct</month>
            <day>03</day>
            <volume>93</volume>
            <issue>7</issue>
            <fpage>740</fpage>
            <page-range>740-3</page-range>
            <pub-id pub-id-type="pmid">16175188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berger</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Regine</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Safran</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Konski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Willett</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>Dec</month>
            <day>20</day>
            <volume>26</volume>
            <issue>36</issue>
            <fpage>5918</fpage>
            <page-range>5918-22</page-range>
            <pub-id pub-id-type="pmid">19029412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Niu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>8</issue>
            <fpage>e103910</fpage>
            <pub-id pub-id-type="pmid">25105762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Konishi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tufts</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jimenez-Rodriguez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cercek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yaeger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saltz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Nash</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Guillem</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Paty</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Garcia-Aguilar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weiser</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome.</article-title>
            <source>JAMA Oncol</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>309</fpage>
            <page-range>309-315</page-range>
            <pub-id pub-id-type="pmid">29270608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niederau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grendell</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers.</article-title>
            <source>Pancreas</source>
            <year>1992</year>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-86</page-range>
            <pub-id pub-id-type="pmid">1557348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Poznak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Somerfield</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Bast</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Cristofanilli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goetz</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Gonzalez-Angulo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lucas</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Mennel</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Symmans</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>LN</given-names>
              </name>
            </person-group>
            <article-title>Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.</article-title>
            <source>J Clin Oncol</source>
            <year>2015</year>
            <month>Aug</month>
            <day>20</day>
            <volume>33</volume>
            <issue>24</issue>
            <fpage>2695</fpage>
            <page-range>2695-704</page-range>
            <pub-id pub-id-type="pmid">26195705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sjoquist</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Renfro</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Simes</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Tebbutt</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maughan</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Saltz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Schmoll</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Douillard</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Hecht</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Tournigand</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Punt</surname>
                <given-names>CJA</given-names>
              </name>
              <name>
                <surname>Koopman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hurwitz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Heinemann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Falcone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Porschen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Diaz-Rubio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aranda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bokemeyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Souglakos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kabbinavar</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Chibaudel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Sargent</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>de Gramont</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zalcberg</surname>
                <given-names>JR</given-names>
              </name>
              <collab>Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD)</collab>
            </person-group>
            <article-title>Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>110</volume>
            <issue>6</issue>
            <fpage>638</fpage>
            <page-range>638-648</page-range>
            <pub-id pub-id-type="pmid">29267900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schiller</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Bonomi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Jan</month>
            <day>01</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>175</fpage>
            <page-range>175-83</page-range>
            <pub-id pub-id-type="pmid">15625371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blackstock</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Herndon</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Paskett</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Graziano</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Muscato</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kosty</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Akerley</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fleishman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2002</year>
            <month>Feb</month>
            <day>20</day>
            <volume>94</volume>
            <issue>4</issue>
            <fpage>284</fpage>
            <page-range>284-90</page-range>
            <pub-id pub-id-type="pmid">11854390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanley</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors for survival in patients with inoperable lung cancer.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>1980</year>
            <month>Jul</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-32</page-range>
            <pub-id pub-id-type="pmid">6930515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17192.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kesson</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Allardice</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women.</article-title>
            <source>BMJ</source>
            <year>2012</year>
            <month>Apr</month>
            <day>26</day>
            <volume>344</volume>
            <fpage>e2718</fpage>
            <pub-id pub-id-type="pmid">22539013</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
